ABSTRACT. Concentrations of I-carnitine and acylcarnitines have been determined in urine from patients with disorders of organic acid metabolism associated with an intramitochondrial accumulation of acyl-CoA intermediates. These included propionic acidemia, methylmalonic aciduria, isovaleric acidemia, multicarboxylase deficiency, 3-hydroxy-3-methylglutaric aciduria, methylacetoacetylCoA thiolase deficiency, and various dicarboxylic acidurias including glutaric aciduria, medium-chain acyl-CoA dehydrogenase deficiency, and multiple acyl-CoA dehydrogenase deficiency. In all cases, concentrations of acylcarnitines were greatly increased above normal with free carnitine concentrations ranging from undetectable to supranorma1 values. The ratios of acylcarnitinelcarnitine were elevated above the normal value of 2.0 f 1.1. I-Carnitine was given to three of these patients; in each case, concentrations of plasma and urine carnitines increased accompanied by a marked increase in concentrations of short-chain acylcarnitines. These acylcarnitines have been examined using fast atom bombardment mass spectrometry in some of these diseases and have been shown to be propionylcarnitine in methylmalonic aciduria and propionic acidemia, isovalerylcarnitine in isovaleric acidemia, and hexanoylcarnitine and octanoylcarnitine in medium-chain acyl-CoA dehydrogenase deficiency. The excretion of these acylcarnitines is compatible with the known accumulation of the corresponding acyl-CoA esters in these diseases.
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In this group of disorders, the increased acylcarnitinel carnitine ratio in urine and plasma indicates an imbalance of mitochondria1 mass action homeostasis and, hence, of acyl-CoAICoA ratios. Despite naturally occurring attempts to increase endogeneous I-carnitine biosynthesis, there is insufficient carnitine available to restore the mass action ratio as demonstrated by the further increase in acylcarnitine excretion when patients were given oral I-carnitine. Thus, I-carnitine insufficiency is a general phenomenon in these diseases. (Pediatr Res 18:1325-1328,1984)
Roe and Bohun (15) observed absence of free I-carnitine in urine of a patient with propionic acidemia (propionyl-CoA carboxylase deficiency), with favorable clinical responses to I-carnitine challenge and treatment. This observation prompted reports of reduced plasma free carnitine in patients with a variety of other metabolic disorders (1, 16) and Seccombe et al. (1 8) also reported increased acylcarnitine to carnitine ratios in a patient with methylmalonic aciduria. Similar observations of reduced plasma carnitine and increased acylcarnitine excretion in a patient with multiple acyl-CoA dehydrogenation defects ("glutaric aciduria type 11") have been made (I I). The importance of measurement of acylcarnitine concentrations in such conditions was undeqlined by the observation that under ketotic conditions acylcarnitine concentrations increase at the expense of free carnitine (12) . This suggests that a shift in mitochondrial metabolite ratios and mass action homeostasis occurs under these circumstances. We have recently studied a patient with methylmalonic aciduria with detailed observations of organic acid, carnitine, and acylcarnitine concentrations in plasma and urine before and during challenge with I-carnitine (16) . Our results have emphasized the importance of measuring acylcarnitines as well as free carnitine and the value of urinary concentrations in assessing the carnitine status and dynamics in such patients. These observations and those of others (1 1) suggest secondary carnitine insufficiency may be a general phenomenon in disorders of organic acid metabolism in which acyl-CoA intermediates accumulate. The present paper reports the results of studies made on urine specimens obtained from 35 patients with such disorders that, together with plasma and urine data during carnitine challenges on selected patients, support this concept. Some of these results have been reported briefly in abstract form elsewhere (6, 7) .
PATIENTS AND METHODS
Urine specimens were obtained from patients with disorders of branched-chain amino acid metabolism, with disorders of Llysine metabolism, and with various nonketotic dicarboxylic acidurias in which the abnormal organic aciduria is consistent with a reduced capacity for @-oxidation. They included seven patients with methylmalonic aciduria including one B12-responsive patient and one patient with combined methylmalonic aciduria and homocvstinuria. two ~atients with isovaleric acidemia (isovaleryl-cod dehydrbgen;se deficiency), two patients with multicarboxylase deficiency (combined deficiencies of pro-pionyl-CoA carboxylase, 3-methylcrotonyl-CoA carboxylase, and pyruvate carboxylase), three patients with 3-hydroxy-3-methylglutaric aciduria (3-hydroxy-3-methylglutaryl-CoA lyase deficiency) and two patients with 2-methyl-3-hydroxybutyric aciduria and tiglylglycinuria (/3-ketothiolase or methylacetoacetyl-CoA thiolase deficiency). The patients with dicarboxylic aciduria included two with glutaric aciduria ("type I"; glutaryl-CoA dehydrogenase deficiency), and one with multiple acyl-CoA dehydrogenase deficiency ("glutaric aciduria type 11"). The five other patients with nonketotic dicarboxylic aciduria included three with medium-chain acyl-CoA dehydrogenase deficiency associated with suberylglycinuria and two others with less well defined disorders. The clinical and biochemical features of all these disorders have been reviewed elsewhere (5) .
All of these patients have been previously diagnosed on the basis of their clinical presentation, abnormal organic aciduria as determined using gas chromatography and mass spectrometry, and demonstration of deficient or abnormal enzyme activity in cultured skin fibroblasts whenever ~ossible. In most cases. the
RESULTS
Concentrations of carnitine and acylcarnitines in urine of patients with propionic acidemia and methylmalonic aciduria are shown in Table 1 . While concentrations of free carnitine range from undetectable to supranormal values, in all cases, the concentrations of acylcarnitines are greatly increased. In particular, the ratio of acylcarnitine/carnitine is elevated above the normal value of 2.0 +. 1.1. Three of these patients (patients 3 and 4 with propionic acidemia and patient 12 with vitamin BIZunresponsive methylmalonic aciduria) have received I-carnitine in single oral doses of 25 (patients 3 and 4) and 100 mg/kg body weight (patient 12). In each case, there was an increase in plasma concentration of free carnitine accompanied by a marked increase in concentrations of short-chain acylcarnitines (Table 2) . Although increases were also observed in plasma long-chain acylcarnitines, these never achieved values within the normal range. Even more marked changes were observed in urine, with very large increases in the concentration of acylcarnitines (Table  diagnosis had been confirmed by biochemical studies in'two 2). centers.
of the patients ranged between 3 months and 12 Table 3 shows the concentrations of free carnitine and acylyears.
carnitines in urine of patients with other disorders of branchedplasma and urine ~-~~~i~i~~ and acylcarnitines were deter-chain amino acid metabolism. In all cases, the acylcarnitine mined using radioenzymatic assays utilizing [~-I~c I~~~~~~-c~A excretion and the acylcarnitine/carnitine ratios are greatly inand carnitine acetyltransferase (3). The concentrations in plasma creased the are expressed in pmol/liter for free camitine, short-chain acid- Table 4 shows the results obtained in ~atients with glutaric soluble acylcarnitines, and longmchain acid-insoluble acylcarni-aciduria and with other metabolic disorders associated with tines. ~h~~~ in urine are expressed in nmol/mg creatinine for increased excretion of dicarboxylic acids. Again, in all patients, free carnitine and acylcarnitines. ~~~~l values for carnitine the excretion of acylcarnitines is greatly increased above normal and acy1carnitine.s in plasma and urine from an adult control with an illcreased ac~lcarnitine/carniti~e ratio. population (n = 10) were used for the present study. Values
The major acylcarnitine excreted by ~atients with methylmaobtained are with those reported elsewhere and to lonic aciduria and with propionic acidemia has been shown to preliminary data obtained in children and adults in the age range be propionylcarnitine. Acylcarnitines excreted by patients with of 3 weeks to 52 years (n = 58) (c. de sou%, R. A. chalmers7 isovaleric acidemia and with medium chain acyl-CoA dehydrogand T. E. stacey, unpublished data). urinary creatinine concen-enase deficiency have been identified as isovalerylcarnitine and trations were determined using an established alkaline picrate as hexanoylcarnitine and octanoylcarnitine, respectively. method.
Acylcarnitines were identified in urine samples using fast atom bombardment mass spectrometry with high resolution mass DISCUSSION measurements and linked scanning techniques as described else-1-Carnitine (3-hydroxy-4-N-trimethylammoniobutanoate) is where ( 16, 1 7) . derived in man both from diet and from endogenous biosynthesis postcarnitine values refer to specimens collected 3 h after the dose was administered. Urine collected between +1 and +3 h. (14) . It has a classical role in the facilitation and modulation of transport of long-chain fatty acyl moieties across the inner mitochondrial membrane and, hence, of mitochondrial @-oxidation (6). Additional newly proposed roles for carnitine recognize the ability of carnitine to act as a cofactor in the transfer of acyl groups out of the mitochondrion, in the reverse direction to the classical role. In particular, the acetyl moiety of acetyl-CoA produced within the mitochondria may be transferred in this manner under ceftain conditions to the cytoplasm. It has been proposed that, by these means, the ratios of the concentrations of acyl-CoA to free CoA within the mitochondrion may be modulated (2, 6) , which would in turn modulate the activity of key mitochondrial processes. Carnitine acyltransferases are steady state enzymes (13) with a random order mechanism (9, 10) relatively independent of pH changes within the physiological range (8) . They follow the mass action route expressed in the ratio will be restored towards the normal mass action value, thereby increasing the availability of free CoA for its other key metabolic roles. The data in this paper provide direct evidence for these concepts. In the patients studied, all of whom have enzyme deficiencies resulting in potential accumulation of intramitochondrial acyl-CoA compounds, there was an increase in excretion of acylcarnitines irrespective of the exact disorder. The precise identities of the acylcarnitines associated with all of the specific diseases remain to be established, but our studies using fast atom bombardment mass spectrometry have shown that the excreted acylcarnitines are compatible with the known intramitochondrial accumulation of t h e i r a~~l -~o~ precursors in the diseases concerned. Thus, propionylcarnitine is the major acylcarnitine excreted by patients with methylmalonic aciduria and propionic acidemia in which propionyl-CoA accumulates, isovalerylcarnitine is excreted by patients with isovaleric acidemia associated with isovaleryl-CoA accumulation, and hexanoylcarnitine and octanoylcarnitine by patients with medium chain acyl-CoA dehydrogenase deficiency. The major acylcarnitine excreted by normal subiects and ~atients with ketosis is acetvlcarnitine.
In addition to the hcreased concentration of &ylcarnitines in the urine of patients with these disorders, there is invariably an increase (often very great) in the ratio of acylcarnitine to free carnitine. This phenomenon is also seen in plasma. We interpret this as reflecting a ~athological ratio of acvl-CoA to free CoA bv the mass actioi p^henom&on. An interesting consequence df this, of potential therapeutic importance, is the possibility that such patients may have insufficient carnitine for these excretory mechanisms to operate to maximum effect. This is paradoxical in that their excretion of total carnitine derivatives may be greatly increased, presumably as a result of supranormal synthesis since dietary sources are relatively normal or even reduced; such patients could scarcely be termed carnitine-deficient. Nevertheless, the concentrations of free carnitine are extremely low in some patients, suggesting that they are synthesizing insufficient carnitine for their increased metabolic needs. Further support for this concept of carnitine insufficiency is proved by the biochemical response shown in some of these patients to an additional oral load of exogenous I-carnitine which results in an even greater excretion of acylcarnitines (7, 16) .
Thus, in this group of disorders, the increased acylcarnitinel carnitine ratio in urine and plasma supports the concept of an imbalance of mitochondrial mass action homeostasis. It is important to note that the acyl-CoA compounds such as propionylCoA that accumulate in these conditions are potentially extremely toxic due to their widespread effects on other metabolic pathways (16) . There appears to be an attempt to compensate for this by increased production of carnitine, resulting in excretion (and hence detoxification at the mitochondrial level) of potentially toxic acyl groups as acylcarnitines. This increased production under basal conditions is apparently still not sufficient to restore the normal mass action ratio for there is further elimination of such acyl groups when patients are given oral Icarnitine. We believe l-carnitine supplementation may have a key role in the general management both acute and longer term of patients with disorders of organic acid metabolism, and our data confirm the necessity to consider acylcarnitine concentrations in addition to that of free carnitine when assessing the metabolic status of these patients.
